Welcome to LookChem.com Sign In|Join Free
  • or
2-[4-(3-carboxyphenyl)-[1,2,3]triazol-1-yl]-1S-(2-thiophen-2-yl-acetylamino)ethaneboronic acid is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1429666-58-9

Post Buying Request

1429666-58-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1429666-58-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1429666-58-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,9,6,6 and 6 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1429666-58:
(9*1)+(8*4)+(7*2)+(6*9)+(5*6)+(4*6)+(3*6)+(2*5)+(1*8)=199
199 % 10 = 9
So 1429666-58-9 is a valid CAS Registry Number.

1429666-58-9Downstream Products

1429666-58-9Relevant academic research and scientific papers

Inhibition of Acinetobacter -Derived Cephalosporinase: Exploring the Carboxylate Recognition Site Using Novel β-Lactamase Inhibitors

Caselli, Emilia,Romagnoli, Chiara,Powers, Rachel A.,Taracila, Magdalena A.,Bouza, Alexandra A.,Swanson, Hollister C.,Smolen, Kali A.,Fini, Francesco,Wallar, Bradley J.,Bonomo, Robert A.,Prati, Fabio

, p. 337 - 348 (2018)

Boronic acids are attracting a lot of attention as β-lactamase inhibitors, and in particular, compound S02030 (Ki = 44 nM) proved to be a good lead compound against ADC-7 (Acinetobacter-derived cephalosporinase), one of the most significant resistance determinants in A. baumannii. The atomic structure of the ADC-7/S02030 complex highlighted the importance of critical structural determinants for recognition of the boronic acids. Herein, to elucidate the role in recognition of the R2-carboxylate, which mimics the C3/C4 found in β-lactams, we designed, synthesized, and characterized six derivatives of S02030 (3a). Out of the six compounds, the best inhibitors proved to be those with an explicit negative charge (compounds 3a-c, 3h, and 3j, Ki = 44-115 nM), which is in contrast to the derivatives where the negative charge is omitted, such as the amide derivative 3d (Ki = 224 nM) and the hydroxyamide derivative 3e (Ki = 155 nM). To develop a structural characterization of inhibitor binding in the active site, the X-ray crystal structures of ADC-7 in a complex with compounds 3c, SM23, and EC04 were determined. All three compounds share the same structural features as in S02030 but only differ in the carboxy-R2 side chain, thereby providing the opportunity of exploring the distinct binding mode of the negatively charged R2 side chain. This cephalosporinase demonstrates a high degree of versatility in recognition, employing different residues to directly interact with the carboxylate, thus suggesting the existence of a carboxylate binding region rather than a binding site in ADC enzymes. Furthermore, this class of compounds was tested against resistant clinical strains of A. baumannii and are effective at inhibiting bacterial growth in conjunction with a β-lactam antibiotic.

Click Chemistry in Lead Optimization of Boronic Acids as β-Lactamase Inhibitors

Caselli, Emilia,Romagnoli, Chiara,Vahabi, Roza,Taracila, Magdalena A.,Bonomo, Robert A.,Prati, Fabio

, p. 5445 - 5458 (2015/08/03)

Boronic acid transition-state inhibitors (BATSIs) represent one of the most promising classes of β-lactamase inhibitors. Here we describe a new class of BATSIs, namely, 1-amido-2-triazolylethaneboronic acids, which were synthesized by combining the asymme

BORONIC ACID INHIBITORS OF BETA-LACTAMASES

-

Page/Page column 61, (2013/04/25)

The invention relates to novel boronic acid compounds, a method for the preparation of such compounds, intermediate compounds for the preparation of such compounds, intermediate compounds for the use in a method for preparation of such compounds, a pharmaceutical composition, the use of one or more compounds discussed above or of a pharmaceutical composition in the manufacture of a medicament for the treatment of a bacterial infection, and a screening method.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1429666-58-9